Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. (3rd September 2018) - Glintborg, B; Kringelbach, T; Bolstad, N; Warren, DJ; Eng, G; Sørensen, IJ; Loft, AG; Hendricks, O; Hansen, IMJ; Linauskas, A; Nordin, H; Kristensen, S; et al.